{"id":"NCT02452190","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils","officialTitle":"A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-28","primaryCompletion":"2017-12-04","completion":"2018-01-31","firstPosted":"2015-05-22","resultsPosted":"2019-02-06","lastUpdate":"2021-11-09"},"enrollment":468,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Reslizumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Reslizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.","primaryOutcome":{"measure":"Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of Treatment","timeFrame":"Day 1 to Week 52","effectByArm":[{"arm":"Placebo","deltaMin":0.52,"sd":null},{"arm":"Reslizumab 110 mg","deltaMin":0.41,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.194"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":226,"countries":["United States","Argentina","Australia","Belgium","Canada","Czechia","France","Germany","Hungary","Israel","Japan","Mexico","New Zealand","Poland","Romania","Russia","South Africa","South Korea","Spain","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["32066536"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":231},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Bronchitis","Acute sinusitis","Rhinitis allergic"]}}